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Abstract
Chronic viral infections are often characterized by CD8 T-cell responses with poor cytokine secretion
potential and limited expansion of the CD8 T-cell pool, collectively referred to as CD8 T-cell
exhaustion. Exhaustion of lymphocytic choriomeningitis virus (LCMV)-specific CD8 T cells was
shown to be partially regulated by the inhibitory receptor programmed death 1 (PD-1). Here, we
demonstrate that exhausted LCMV-specific CD8 T cells also express the negative regulatory receptor
lymphocyte activation gene 3 (LAG-3) which is mainly expressed on cells co-expressing the negative
regulatory receptors PD-1 and Tim-3. Expression levels of LAG-3 on anti-viral CD8 T cells remain
stable over short-term in vitro stimulations in presence of antigenic peptide. Nevertheless, in vitro and
in vivo blockade of LAG-3 did not rescue cytokine production by virus-specific CD8 T cells and did not
alter the virus titer in various organs. Likewise, chronic LCMV infection of LAG-32/2 mice led to
a comparable degree of T-cell exhaustion as observed in C57BL/6 controls and to similar virus titers.
Further, LAG-3 did not influence T-cell activation or cell division during chronic LCMV infection.
These data suggest that even though LAG-3 is continuously up-regulated on LCMV-specific
exhausted CD8 T cells, it alone does not significantly contribute to T-cell exhaustion.
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Introduction
Unlike after acute resolved infections, the development of
long-lived antigen-independent memory CD8 T cells that
can rapidly exert effector functions is precluded during
chronic viral infections (1, 2). During chronic viral infections
(i.e. human infection with HIV, hepatitis B or hepatitis C vi-
rus), virus-specific CD8 T cells acquire effector functions
early after infection but gradually lose them as the antigen
persists over extended time periods (3–8). This T-cell dys-
function, also termed CD8 T-cell exhaustion, is well studied
after chronic infection of mice with lymphocytic choriomenin-
gitis virus (LCMV) Clone 13 or LCMV Docile (9). In this set-
ting, the LCMV-specific CD8 T-cell pool expands early after
infection and acquires effector functions, which, however,
are not sufficient to control viral replication. As a result of
the ensuing continuous presence of viral antigen, LCMV-
specific CD8 T cells are continuously stimulated which leads
to gradual decline of their effector functions: first the ability
to produce IL-2 and to proliferate, then tumor necrosis factor
a (TNFa) secretion and last IFN-c production is decreased
(10–13). Although degranulation of CD8 T cells and killing of
target cells was also reported to be impaired (12), this is not
a consistent finding (10). The above scenario is observed for
CD8 T cells with specificities for the LCMV glycoprotein-
derived peptides gp33 and gp276, whereas CD8 T cells with
specificity for the LCMV epitope np396 are physically deleted
during protracted LCMV infection (9, 11).
Recent work has highlighted the role of inhibitory recep-
tors in inducing/maintaining exhausted CD8 T cells (14–18).
Programmed death 1 (PD-1), an inhibitory receptor of the
CD28 superfamily (19), was shown to be expressed at ele-
vated levels on exhausted CD8 T cells compared with func-
tional memory T cells in the LCMV system (16). Blockade of
PD-1/ programmed death ligand 1 (PD-L1) interactions after
chronic LCMV infection not only increased the numbers of
LCMV-specific CD8 T cells but also enhanced their functional-
ity resulting in decreased virus titers (16). However, functional
restoration was not complete, suggesting the involvement of
other negative regulatory pathways in CD8 T-cell exhaustion.
CTLA-4 (cytotoxic T lymphocyte antigen 4), another CD28
family member, is also up-regulated on CD8 T cells after
chronic LCMV infection [(18) and K. Richter, P. Agnellini and
A. Oxenius, unpublished results]. However, in vivo CTLA-4
blockade in chronically LCMV-infected mice did not increase
T-cell functionality (16).
Gene expression profiling revealed a strong up-regulation
of the inhibitory receptor lymphocyte activation gene 3
(LAG-3) on LCMV-specific CD8 T cells in chronically LCMV-
infected mice compared with CD8 T cells from acutely
infected mice [K. Richter, P. Agnellini and A. Oxenius, unpub-
lished results (18)]. LAG-3 (CD223) is an activation-induced
cell surface molecule that is structurally similar to the CD4
molecule and binds to MHC II molecules with high affinity
(20, 21). LAG-3 blockade was shown to induce CD69 expres-
sion on CD4 and CD8 T cells and to induce T-cell expansion
and production of Th1 cytokines in resting human T cells (22).
As murine LAG-3/ OTII T-cells secrete more IL-2 and IFN-
c following stimulation than their wild-type counterparts (23)
and as LAG-3/ T cells showed increased T-cell expansion
in vivo after Sendai virus infection (24), LAG-3 was chosen
as candidate inhibitory molecule that might have a role in
dampening the CD8 T-cell response in chronic LCMV infec-
tion. In this study, we show that LAG-3 is up-regulated on
LCMV-specific CD8 T cells after chronic LCMV infection. Nev-
ertheless, neither antibody-mediated blockade in vivo nor
use of LAG-3 knockout mice led to increased T-cell effector
functions or reduction of viral titers compared with control
treated, respective wild-type mice, indicating that LAG-3
alone does not majorly contribute to CD8 T-cell exhaustion.
Methods
Virus and viral peptides
LCMV Docile was propagated on MDCK cells, whereas
LCMV Clone 13 was propagated on BHK21 cells as de-
scribed (25). Viral peptides gp33–41 (gp33; KAVYNFATM),
np396–404 (np396; FQPQNGQFI) and gp61–80 (p13;
LNGPDIYKGVYQFKSVEFD) were purchased from NeoMPS
(Strasbourg, France).
Antibodies and peptide MHC I tetramers
Allophycocyanin or PE-conjugated peptide/MHC I tetrameric
complexes were generated as described (26). Rat anti-LAG-
3 IgG2a antibodies used for in vivo blocking experiments
were received from Klaus Karjalainen (27), Singapore.
Blocking antibodies directed against LAG-3, CTLA-4 and
PD-L1 that were used in in vitro experiments were pur-
chased from eBioscience (THP, Vienna, Austria). Antibod-
ies used for flow cytometry were purchased from BD
Pharmingen (Allschwil, Switzerland) and Biolegend (Lucer-
naChem, Luzern, Switzerland).
Mice
Mice were kept under specific pathogen-free conditions and
were infected intravenously (i.v.) with 200 pfu or 106 pfu of
LCMV strains Docile or Clone 13. When indicated, mice
were treated in vivo with 200 lg anti-LAG-3 by intraperito-
neal administration either on days 3, 1, 3, 6, 9, 12 and
15 or on days 39, 42, 45, 48 and 51 post-infection. Animal
experiments were performed according to the regulations of
the cantonal veterinary office.
Stimulation of lymphocytes and flow cytometry
Lymphocytes were harvested from the spleens of perfused
mice and stimulated with 1 lg ml1 gp33, np396 or p13
peptide in the presence of Brefeldin A (10 lg ml1; Sigma-
Aldrich, St. Louis, MO, USA) and Monensin A (2 lM; Sigma-
Aldrich) for 5 h at 37C. For assessment of degranulation,
1 ll anti-mouse CD107a was added during the stimulation.
Where indicated, the cells were pre-treated for 1 h or 2 days
with 10 lg ml1 of blocking antibodies directed against
LAG-3, CTLA-4 and/or PD-L1 [functional grade purified;
eBioscience (THP)] before stimulation was continued in the
presence of antibodies. During 2 day pre-treatment, the
cells were incubated in RPMI containing 100 U ml1 IL-2
and 100 ng ml1 IL-15 (Biosource, Nivelles, Belgium).
Surface staining was performed for 30 min at 4C before
the cells were fixed and permeabilized in 500 ll 23 FacsLyse
(BD Biosciences, Allschwil, Switzerland) containing 0.05%
Tween 20 (Sigma-Aldrich) for 10 min at room temperature. Af-
ter a wash step, cytokines were stained for 30 min at room
temperature. Cells were washed and re-suspended in PBS
containing 1% PFA (Sigma-Aldrich). Multiparameter flow cyto-
metric analysis was performed using an FACS LSRII flow
cytometer (BD Biosciences, Allschwil, Switzerland) with
FACSDiva software. Analysis was performed using FlowJo
software (Tree Star, San Carlos, CA, USA).
Results
LAG-3 is up-regulated during chronic LCMV infection
Comparative gene profiling analyses of LCMV-specific CD8
T cells during acute or chronic LCMV infection revealed
a marked up-regulation of LAG-3 expression in the setting of
chronic LCMV infection [for chronic LCMV Docile infection
(K. Richter, P. Agnellini and A. Oxenius, unpublished results)
and for LCMV Clone 13 infection (18)]. To assess if LAG-3 was
not only up-regulated on mRNA level but also on protein level
during chronic LCMV infection, C57BL/6 mice were acutely or
chronically infected with LCMV strains Docile or Clone 13 and
analyzed for LAG-3 expression on endogenous CD8 T cells
specific for the LCMV-derived peptide epitope gp33. On day
13 post-infection, gp33-specific CD8 T cells from acutely
infected mice showed only slightly elevated expression com-
pared with LAG-3/ CD8 T cells, while LAG-3 expression
on gp33-specific CD8 T cells from chronically infected mice
was markedly up-regulated (Fig. 1A and B). Note that LAG-3
expression was slightly stronger in Docile compared with
Clone 13-infected mice. Next, we analyzed if LAG-3 is co-
expressed with the inhibitory receptor PD-1 which is in-
volved in CD8 T-cell exhaustion after chronic LCMV infection
(16) on endogenous anti-viral CD8 T cells. We observed that
most cells expressing LAG-3 also expressed PD-1 after
Clone 13 infection or after Docile infection (Fig. 1B).
As endogenous CD8 T-cell populations specific for a cer-
tain epitope comprise polyclonal T cells with presumably dif-
ferent TCR affinities for the epitope, we went on to assess
LAG-3 expression on transferred Ly5.1+ TCR transgenic
CD8 T cells specific for the gp33 peptide after acute and
chronic infection with LCMV Docile. This monoclonal popula-
tion of T cells showed a similar expression pattern compared
with the endogenous polyclonal population with respect to
up-regulation of LAG-3, PD-1 and additionally of the inhibi-
tory receptor Tim-3 that was shown to be up-regulated on
exhausted CD8 T cells during HIV infection (28). Again,
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LAG-3 was largely co-expressed with other inhibitory
receptors, in particular with PD-1 (Fig. 1D).
T-cell priming is similar in LAG-3/ and wild-type mice
To analyze if LAG-3 influences the priming of CD4 and CD8
T cells in the context of LCMV infection, C57BL/6 and LAG-
3/ mice were acutely infected with LCMV Clone 13 or
Docile and assessed for the frequency of LCMV-specific
CD8 T cells with the ability to degranulate upon antigen-
specific re-stimulation. The frequency of degranulating CD8
T cells was similar in LAG-3/ mice and C57BL/6 controls
after Clone 13 infection (as assessed by CD107a staining,
Fig. 2A) and after Docile infection (Fig. 2B). Likewise, similar
frequencies of CD8 T cells secreting IFN-c (Fig. 2C), TNFa
(Fig. 2D) and IL-2 (Fig. 2E) were measured in LAG-3/
and C57BL/6 mice after stimulation with the antigenic pepti-
des gp33 and np396 on day 13 post-infection with LCMV
Docile. Comparable results were obtained after infection with
Clone 13 (data not shown). Furthermore, the frequency of
LCMV-specific CD4 T cells secreting IFN-c (Fig. 1F) and
TNFa (Fig. 1G) after stimulation with p13 peptide were com-
parable in LAG-3/ and C57BL/6 mice. Thus, LAG-3 does
not influence the quality or quantity of T-cell priming upon
acute LCMV infection.
Fig. 1. LAG-3 is up-regulated after chronic LCMV infection and is mainly co-expressed with the inhibitory receptor PD-1. (A) C57BL/6 mice were
i.v. infected with 106 (dashed) or 200 pfu (black) of LCMV strains Docile or Clone 13. LAG-3/mice infected with 200 pfu of the respective virus
served as negative control (dotted). Spleen single-cell suspensions were analyzed for the expression of LAG-3 on H-2Db-gp33-tetramer+ CD8
T cells by flow cytometry on day 13 post-infection. One representative staining of three to four mice per group is shown. Data in the table
represent the means of the mean fluorescence intensities. (B) Co-expression of LAG-3 and PD-1 was examined on H-2Db-gp33-tetramer+ CD8
splenocytes after i.v. infection with 106 pfu of LCMV Docile or Clone 13. (C) Expression of the inhibitory receptors PD-1, LAG-3 and Tim-3 was
analyzed on Ly5.1+ TCR transgenic CD8 Tcells specific for gp33 that were transferred 1 day before acute or chronic infection with LCMV Docile.
Splenocytes were analyzed on day 18 post-infection. One representative staining of three mice per group is shown. (D) Analysis of co-expression
of inhibitory receptors; cells are gated on CD8 Ly5.1+ TCR transgenic T cells.
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Expression of LAG-3 on LCMV-specific CD8 T cells does not
decrease during short-term stimulations in the presence of
antigenic peptide
As it was reported that LAG-3 can be cleaved at the cell sur-
face by ADAM 10 and ADAM 17 metalloproteases allowing
cytokine production and proliferation (29), we measured
LAG-3 expression during short-term stimulations in the pres-
ence of antigenic peptide. A total of 104 TCR transgenic
CD8 T cells specific for the LCMV-derived gp33 peptide
were transferred i.v. into C57BL/6 recipients 1 day before
chronic infection. On day 18 post-infection, the transferred
TCR transgenic CD8 T cells were re-stimulated in vitro for
5 h in presence or absence of gp33 peptide and LAG-3 sur-
face expression was analyzed. LAG-3 expression did not
significantly decrease upon stimulation (Fig. 3), indicating
that signaling events via LAG-3 can occur in vivo in temporal
proximity to TCR stimulation.
Stimulation of CD8 T cells in the presence of a blocking
antibody directed against LAG-3 does not rescue exhausted
phenotype
To analyze the effect of LAG-3 blockade on exhausted
T cells, we investigated short-term changes in T-cell effector
functions in the presence of blocking antibodies in vitro.
One hour pre-incubation with various blocking antibodies, in-
cluding anti-LAG-3, did not restore any cytokine defects
within CD8 T cells from chronically LCMV-infected mice.
However, a 2-day resting period prior to peptide stimulation
markedly increased the cytokine production potential within
CD8 T cells originating from chronically infected mice
(Fig. 4). However, this partial rescue of cytokine production
in this short-time period occurred irrespective of whether
blocking antibodies (specific for LAG-3, PD-L1 or CTLA-4 or
Fig. 2. T-cell priming is similar in LAG-3/ and C57BL/6 mice. C57BL/6 and LAG-3/ mice were i.v. infected with 200 pfu of LCMV Clone 13
(A) or LCMV Docile (B–G). Splenocytes were analyzed on day 13 post-infection for the ability of CD8 T cells to degranulate (as assessed by
CD107 staining; A and B) and to produce IFN-c (C), TNFa (D) and IL-2 (E) after 5 h of stimulation in the presence of gp33 respective np396
peptide. CD4 T cells were analyzed for production of IFN-c (F) and TNFa (G) after stimulation with p13 peptide. Background staining was
substracted from the measured value of each individual mouse. Horizontal lines indicate the arithmetic means of each group of mice while boxes
show minimum and maximum of the measured values.
Fig. 3. LAG-3 expression is maintained after stimulation with gp33.
A total of 104 Ly5.1+ TCR transgenic CD8 T cells were transferred into
C57BL/6 and LAG-3/ mice 1 day before i.v. infection with 200 or
106 pfu LCMV Docile. On day 18 post-infection, splenocytes were
stimulated in the presence of Brefeldin A and in presence or absence
of gp33 for 5 h. LAG-3 expression was analyzed on Ly5.1+ TCR
transgenic CD8 T cells. Each symbol represents one individual
mouse. Horizontal bars indicate mean values of each group. Data are
representative of two independent experiments.
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combinations thereof) were present during the 2-day recov-
ery period or not.
In vivo treatment of chronically LCMV-infected mice with an
anti-LAG-3 blocking antibody does not rescue T-cell
exhaustion and does not lead to decreased viral titers
Next, we decided to block LAG-3 in vivo. If LAG-3 plays
a crucial role in inhibiting T-cell effector functions during
chronic LCMV infection, we would expect that LAG-3 block-
ade should elevate cytokine production by CD8 T cells and/
or increase the frequency of LCMV-specific CD8 T cells,
which could eventually also lead to a decrease in virus titers.
In a first experiment, C57BL/6 mice were chronically infected
and treated with anti-LAG-3 or PBS on days 39 until day 51
every 3 days (Fig. 5A). Acutely infected C57BL/6 mice
served as controls. On day 54 post-infection, the frequency
of gp33-specific CD8 T cells (Fig. 5B) and the capacity to
degranulate (Fig. 5C) or secrete IFN-c (Fig. 5D) after 5 h
stimulation with gp33 was not different in anti-LAG-3-treated
chronically infected mice compared with PBS-treated chroni-
cally infected mice. Viral titers between anti-LAG-3-treated
and PBS-treated chronically infected C57BL/6 mice were
monitored in the blood over time and did not change in the
anti-LAG-3-treated group compared with the control group
(Fig. 5E). Note that the viral titers were already slightly lower
in the anti-LAG-3-treated group before the treatment was
started on day 39 post-infection.
Fig. 4. Short-term stimulation of CD8 T cells in the presence of a blocking antibody directed against LAG-3 does not rescue exhausted
phenotype. Groups of three C57BL/6 mice were either infected with 200 (acute) or 106 (chronic) pfu LCMV Docile. On day 16 post-infection,
splenocytes were seeded at 4 3 106 per well with the indicated blocking antibodies directed against LAG-3, CTLA-4 and PD-L1. After 1 h or 2
days, gp33 was added and the cells were incubated another 5 h before being stained against CD8, CD107 and IFN-c. Negative controls (Ø)
were incubated without gp33. (A) The ratio of CD8 Tcells producing IFN-c per CD107+ cells is shown. (B) Representative FACS plots from day 2
gated on CD8 T cells are depicted.
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Fig. 5. In vivo treatment of chronically LCMV-infected mice with an anti-LAG-3 blocking antibody does not rescue T-cell exhaustion and does not
lead to decreased viral titers. (A–E) Groups of three C57BL/6 mice were infected with 200 pfu (low dose, ld) or 106 pfu Docile (high dose, hd) as
indicated and treated with PBS or 200 lg of a blocking antibody directed against LAG-3 on days 39, 42, 45, 48 and 51 (A). On day 54 post-
infection, the splenocytes were stained for CD8 and H-2Db-gp33-tetramer (B) or re-stimulated in the presence of gp33 and analyzed for the
capacity of CD8 T cells to degranulate (C) and produce IFN-c (D). Background staining was substracted. (E) Virus titers in the blood were
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As therapeutic blockade of LAG-3 did not increase CD8
effector functions, we investigated whether anti-LAG-3 treat-
ment initiated already during acute infection would influence
CD8 T-cell exhaustion and viral control. Thus, chronically
infected C57BL/6 mice were treated during the whole course
of infection from day 3 until day 15 post-infection (Fig. 5F).
Also in this experimental setting, degranulation and IFN-c se-
cretion of gp33-stimulated CD8 T cells were similar in anti-
LAG-3-treated and control-treated mice (Fig. 5G and H). Vi-
ral titers in the blood were not significantly different between
anti-LAG-3-treated and PBS-treated mice on day 9 and day
17 post-infection (Fig. 5I). Also, LAG-3 blockade did not im-
pact on virus titers in spleen (Fig. 5J), lung (Fig. 5K), liver
(Fig. 5L) and kidney (Fig. 5M). Thus, in vivo blockade of
LAG-3–MHC II interactions neither induced improved CD8
T-cell effector functions in a therapeutic setting nor when
mice were treated during the whole course of the experi-
ment. Therefore, a potential inhibitory function of LAG-3
does not seem to be very crucial for T-cell exhaustion.
Chronic infection of LAG-3/ and wild-type mice with LCMV
Docile induces similar degree of T-cell exhaustion and similar
viral titers.
As antibody-mediated blockade of LAG-3–MHC II interac-
tions did not prove to rescue T-cell exhaustion, it is conceiv-
able that this could be due to insufficient in vivo blockade of
the LAG-3 pathway. We therefore used LAG-3 knockout mice
for chronic LCMV infections. Neither the frequency of gp33-
tetramer+ CD8 T cells nor of np396-tetramer+ CD8 T cells in
the blood was different between LAG-3/ and C57BL/6
controls chronically infected with LCMV Docile (Fig. 6A and
B). Similar results were obtained after Clone 13 infection
(Supplementary Fig. 1 is available at International Immunol-
ogy Online). Also, short-time stimulation of splenocytes with
gp33 respective np396 peptide did not yield increased IFN-c
production (Fig. 6C and E) and TNFa (Fig. 6D and F) secre-
tion by CD8 T cells from chronically infected mice at any time
point analyzed. Likewise, after chronic infection of LAG-3/
and C57BL/6 mice with LCMV strain Clone 13, no difference
in the frequency of degranulating (Supplementary Fig. 1E
and H is available at International Immunology Online), IFN-c
(Supplementary Fig. 1F and I is available at International Im-
munology Online) and TNFa (Supplementary Fig. 1G and J is
available at International Immunology Online) producing CD8
T cells was observed after a 5-h stimulation with gp33 and
np396 peptides.
Similarly, when splenocytes from LCMV Docile-infected
LAG-3/ and C57BL/6 mice were stimulated with the CD4
T-cell epitope p13 (30), no elevation of IFN-c (Fig. 6G) or
TNFa (Fig. 6H) production was observed in absence of
LAG-3 on days 13, 39 and 58 post-infection. Further, CD4
T cells were similarly exhausted in chronically Clone 13-
infected C57BL/6 and LAG-3/ mice and did not produce
significant amounts of IFN-c (Supplementary Fig. 1K is avail-
able at International Immunology Online) and TNFa (Supple-
mentary Fig. 1L is available at International Immunology
Online).
If altered T-cell effector functions had been present at time
points that were not included in this analysis, this could be
reflected in viral titer. As viral titers in blood, lymph node,
spleen, liver, lung, kidney and brain are similar in C57BL/6
and LAG-3/ mice on days 13, 35 and 58 post-infection
with LCMV Docile, this is rather unlikely (Fig. 6I). Similar
titers were also observed in Clone 13-infected LAG-3/
and C57BL/6 mice (Supplementary Fig. 1M is available at
International Immunology Online).
Thus, LAG-3/ mice compared with C57BL/6 mice
showed improved CD8 T-cell effector functions and/or re-
duced virus titers neither after LCMV Docile infection nor af-
ter LCMV Clone 13 infection. Therefore, a potential inhibitory
function of LAG-3 alone does not seem to be very crucial
for T-cell exhaustion.
The degree of T-cell exhaustion was also analyzed by as-
sessment of the expression of the inhibitory receptor PD-1.
Interestingly, PD-1 was expressed at similar levels in LAG-
3/ and C57BL/6 mice, but on a smaller frequency of
gp33-specific CD8 T cells derived from spleen of Clone 13-
infected mice than from Docile-infected mice (Fig. 7A). The
difference between the virus strains was not apparent if
gp33-specific CD8 T cells from blood were analyzed
(Fig. 7B), probably reflecting migration of exhausted spleno-
cytes to the periphery.
As LAG-3 was reported to affect T-cell proliferation (17,
23), we next examined whether in vivo T-cell division was al-
tered in LAG-3/ compared with C57BL/6 mice after
chronic infection with LCMV strains Docile respective Clone
13. We did not observe any substantial differences in the fre-
quency of Ki67+ gp33-tetramer+ CD8 T cells derived from
spleen (Fig. 7C) and blood (Fig. 7D). Similar proliferation
might also account for the similar frequency of gp33-specific
CD8 T cells observed in LAG-3/ and C57BL/6 mice after
chronic LCMV infection (Fig. 6 and Supplementary Fig. 1 is
available at International Immunology Online).
Interestingly, the frequency of Ki67+ gp33-specific CD8
T cells is higher in blood than in spleen, possibly reflecting
migration of recently activated/proliferating cells from sec-
ondary lymphoid organs to peripheral tissues via the blood
circulation.
Discussion
In this report, we investigated the expression and impor-
tance of the inhibitory receptor LAG-3 on CD8 T cells during
determined on days 15, 28, 39, 52 and 54. (F–M) Groups of three C57BL/6 mice were infected with 200 (low dose, ld) or 106 pfu Docile (high
dose, hd) as indicated and treated with PBS or 200 lg of a blocking antibody directed against LAG-3 on days 3, 1, 3, 6, 9, 12 and 15 (F). On
day 17 post-infection, splenocytes were re-stimulated with gp33 for 5 h and analyzed for the capacity of CD8 T cells to degranulate (G) and to
produce IFN-c (H). Background staining was substracted. Virus titers in the blood were determined on days 9 and 17 post-infection (I). On day 17
post-infection, virus titers were determined in spleen (J), lung (K), liver (L) and kidney (M). One representative of two experiments is shown. Each
symbol represents the measured value of one individual mouse. Horizontal lines indicate the arithmetic means of each group of mice. Dashed
lines indicate the detection limits.
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Fig. 6. Chronic infection of LAG-3/ and wild-type mice with LCMV Docile induces similar degree of T-cell exhaustion and similar viral titers.
Groups of three to five LAG-3/ and C57BL/6 mice were i.v. infected with 106 pfu LCMV Docile and sacrificed on days 13, 39 and 58 post-
infection. The frequencies of H-2Db-gp33- (A) and H-2Db-np396- (B) tetramer+ CD8 T cells were determined in blood. Splenocytes were re-
stimulated with gp33 (C and D) and np396 (E and F) and analyzed for the capacity of CD8 Tcells to produce IFN-c (C and E) and TNFa (D and F).
CD4 T cells were stimulated with p13 peptide and assessed for their ability to produce IFN-c (G) and TNFa (H). Virus titers were determined in
blood, lymph nodes, spleen, liver, lung, kidney and brain (I). Each symbol represents the measured value of one individual mouse. Horizontal
lines indicate the arithmetic means of each group of mice. Dashed lines indicate the detection limits.
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acute and chronic LCMV infection. We could demonstrate
that exhausted virus-specific CD8 T cells express elevated
levels of LAG-3. LAG-3 was mainly expressed on cells co-
expressing other inhibitory receptors as PD-1, an inhibitory
receptor involved in T-cell exhaustion during LCMV infection
(16), and Tim-3, an inhibitory receptor expressed by HIV-
specific CD8 T cells (28). These data support and extend
data from Blackburn et al. describing complex expression
patterns of various inhibitory receptors on exhausted CD8
T cells (17). Interestingly, the expression levels of LAG-3 on
gp33-specific CD8 T cells were higher after chronic infection
with LCMV strain Docile than with strain Clone 13. This might
reflect the different severity of T-cell exhaustion in Clone 13
versus Docile infection, with LCMV Docile infection leading
to more severe exhaustion (10, 12, 16).
In vitro blockade of LAG-3, also in combination with anti-
PD-L1 and/or anti-CTLA-4, did not elevate cytokine produc-
tion in short-term stimulations of splenocytes from chronically
infected mice. Similarly, we (10) and others (17, 31) have
previously shown that short-term PD-L1 blockade does not
restore T-cell functionality. However, PD-L1 blockade was
shown to have a beneficial effect during longer stimulation
periods (16). Thus, blockade of inhibitory receptor signaling
on exhausted CD8 T cells does not lead to immediate resto-
ration of their functionality but seems to require a ‘rejuvenat-
ing’ proliferation period to gain enhanced effector functions
(10, 31).
Next, we showed that the presence of LAG-3 is not crucial
for T-cell priming during acute LCMV infection. This is a pre-
requisite to be able to compare T-cell exhaustion during
chronic viral infection with and without LAG-3 signals. If mu-
rine LAG-3 can function as negative regulator of activated
T cells as it was described for human, the inhibitory role of
LAG-3 (20, 32) is controversial as the first analysis of the in-
hibitory role of LAG-3/ mice did not reveal a defect in
T-cell function with respect to activated and memory sub-
populations of CD4 and CD8 T cells and their responses to
mitogens and to antigen priming (33). However, in more re-
cent studies, it could be shown that murine LAG-3/ OTII
T cells secrete more IL-2 and IFN-c following peptide stimu-
lation than their wild-type counterparts (23) and that LAG-
3/ T cells expanded more vigorously in vivo after Sendai
virus infection than wild-type T cells (24). In vivo blockade or
genetic ablation of the Lag-3 gene also led to increased ac-
cumulation and effector function of antigen-specific CD8 T
cells within tumors and organs that express cognate antigen
(34), but in this system, PD-1 and LAG-3 are expressed on
different subsets of CD8 T cells (35). Nevertheless, in our
experiments, no crucial contribution of LAG-3 during T-cell
priming in acute LCMV infection could be observed and
goes along with the low and transient expression of LAG-3
on LCMV-specific CD8 T cells after acute LCMV infection.
Despite the fact that initial T-cell priming during LCMV in-
fection was not altered in LAG-3/ mice, it was still possible
Fig. 7. Expression of PD-1 and proliferation marker Ki67 is unaltered in LCMV-specific CD8 Tcells from LAG-3/mice compared with C57BL/6
mice after chronic infection with LCMV Docile or Clone 13. LAG-3/ and C57BL/6 mice were i.v. infected with 106 pfu LCMV Docile or Clone 13
and sacrificed on day 58 post-infection. Expression of PD-1 on H-2Db-gp33-tetramer+ CD8 T cells derived from spleen (A) and blood (B) was
assessed. A mouse that was transferred with 104 TCR transgenic CD8 Tcells and infected with 200 pfu LCMV-WE several months before analysis
served as control (memory). Intracellular expression of Ki67 was analyzed on H-2Db-gp33-tetramer+ CD8 T cells derived from spleen (C) and
blood (D). Each symbol represents the measured value of one individual mouse. Horizontal lines indicate the arithmetic means of each group of
mice.
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that sustained LAG-3 expression on LCMV-specific CD8
T cells during chronic infection might critically contribute to
their dysfunction. However, in vivo blockade of LAG-3 during
an established chronic infection or during the whole course
of an infection did not rescue cytokine production by virus-
specific CD8 T cells, or change the frequency of LCMV-
specific CD8 T cells or alter the virus titer in various organs.
The finding that therapeutic treatment of mice with anti-LAG-
3 alone did not rescue exhausted T cells was recently
reported by another group (17). Nevertheless, even though
no differences were observed in mice treated with anti-LAG-3
and untreated mice with respect to cytokine production,
slightly decreased virus titers were observed in the study by
Blackburn et al. (17) as opposed to our study using in vivo
LAG-3 blockade or LAG-3/ mice. The reasons for this dis-
crepancy are currently unclear.
We observed that expression levels of LAG-3 on anti-viral
CD8 T cells remained stable over short-term in vitro stimula-
tions in the presence of antigenic peptide. It was previously
shown that cleavage of LAG-3 by the metalloproteases
ADAM 10 and ADAM 17 regulated T-cell proliferation and ef-
fector function (29). The unaltered expression of LAG-3 upon
antigenic stimulation indicates that repetitive in vivo stimula-
tion of LCMV-specific CD8 T cells, as it is likely the case dur-
ing chronic LCMV infection, does not lead to LAG-3
cleavage, thus maintaining the potential inhibitory function
of LAG-3-mediated signals. However, as both in vivo block-
ade and the use of LAG-3/ mice did not show any
changes in T-cell function or control of viral replication upon
chronic LCMV infection, we conclude that inhibitory signals
mediated via LAG-3 alone are not critically involved in CD8
T-cell exhaustion.
Further, the presence of LAG-3 did not influence T-cell di-
vision of gp33-specific CD8 T cells after chronic LCMV infec-
tion as assessed by expression of Ki67. This is in contrast to
gp276-specific CD8 T cells after chronic LCMV infection
which showed increased proliferation after in vivo LAG-3
blockade (17). Whether this difference is due to the different
T-cell specificity is currently unclear.
These data in combination with the data from Blackburn et al.
(17) suggest that even though LAG-3 is up-regulated on
LCMV-specific exhausted CD8 T cells, it does not significantly
contribute to T-cell exhaustion alone. To effectively interfere
with T-cell exhaustion, it is very likely that several inhibitory
receptors will have to be targeted simultaneously (17).
Supplementary data
Supplementary Fig. 1 is available at International Immunology
Online.
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